机构：[1]Department of Cardiology, Southwest Hospital, Third MilitaryMedical University, Chongqing, China[2]Department of Cardiology,Xinqiao Hospital, Third Military Medical University, Chongqing,China[3]Department of Cardiology, Daping Hospital, Third MilitaryMedical University, Chongqing, China[4]Department of Cardiology,The Second Affiliated Hospital of Chongqing Medical University,Chongqing, China[5]Department of Cardiology, The Second AffiliatedHospital of Hebei Medical University, Hebei, China[6]Department ofCardiology, Harrison International Peach Hospita, Hebei, China[7]Department of Cardiology, the Forth Affiliated Hospital of HebeiMedical University, Hebei, China[8]Department of Cardiology, HenanProvincial People Hospital, Henan, China
第一作者机构：[1]Department of Cardiology, Southwest Hospital, Third MilitaryMedical University, Chongqing, China
推荐引用方式(GB/T 7714)：
Shu M.Q.,Song Z.Y.,Jing T.,et al.MILDRONATE VERSUS LEVOCARNITINE IN PATIENTS WITH ISCHEMIC HEART DISEASE: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, NON-INFERIORITY TRIAL[J].BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY.2014,115:2-2.
APA：
Shu M.Q.,Song Z.Y.,Jing T.,Zhang Q.,Song Y.M....&She B.R..(2014).MILDRONATE VERSUS LEVOCARNITINE IN PATIENTS WITH ISCHEMIC HEART DISEASE: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, NON-INFERIORITY TRIAL.BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY,115,
MLA：
Shu M.Q.,et al."MILDRONATE VERSUS LEVOCARNITINE IN PATIENTS WITH ISCHEMIC HEART DISEASE: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, NON-INFERIORITY TRIAL".BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY 115.(2014):2-2
